Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit?

Troy Walker, Simone Sherriff, Jennifer Browne

Abstract read

In one paragraph

Article in The Medical journal of Australia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Troy WalkerInstitute for Health Transformation, Global Centre for Preventive Health and Nutrition, School of Health and Social Development, Faculty of Health Deakin University, Geelong, Victoria, Australia.

Simone SherriffPoche Centre for Indigenous Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

Jennifer BrowneInstitute for Health Transformation, Global Centre for Preventive Health and Nutrition, School of Health and Social Development, Faculty of Health Deakin University, Geelong, Victoria, Australia.

Funding

National Health and Medical Research Council 2035274

6 · The paper itself

Abstract

The growing popularity of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has driven off-label prescriptions and supply shortages, raising equity concerns for First Nations peoples disproportionately affected by diabetes. Pharmaceutical companies have simultaneously accelerated their marketing through disease-awareness campaigns, sponsored events and telehealth models, with many campaigns prominently featuring women of colour, including First Nations women. In this perspective article, we argue, from a commercial determinants of health perspective, that pharmaceutical companies often influence perceptions of body image, medicines policy and prescribing without addressing the systemic conditions driving First Nations health inequity. We urge clinicians and policymakers to ensure decisions remain free from commercial influence.

Indexed as

Anti-Obesity AgentsDiabetes Mellitus, Type 2Drug IndustryGlucagon-Like Peptide-1 Receptor AgonistsMarketingAustraliaAustralian Aboriginal and Torres Strait Islander PeoplesFemaleHumansAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor Agonistsadvertising as topicpharmaceuticalspublic health educationsocial media

Identifiers

PMID42429319

DOI10.5694/mja2.70246

PMCPMC13353042

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.